Minimally invasive partial nephrectomy (MIPN) has become the gold standard for surgical treatment of small renal masses, and techniques have proliferated to decrease ischemia time, prevent complications, and improve outcomes. Dogma mandates that collecting system be closed after tumor excision to prevent postoperative urine leak, but our experience suggests that this step is not necessary, and may actually increase the risk of compromising underlying structures. We report our experience with MIPN without collecting system closure for patients at high risk of urine leak, as determined by parameters described in the urologic literature.
INTRODUCTION AND OBJECTIVES:
Minimally invasive partial nephrectomy (MIPN) has become the gold standard for surgical treatment of small renal masses, and techniques have proliferated to decrease ischemia time, prevent complications, and improve outcomes. Dogma mandates that collecting system be closed after tumor excision to prevent postoperative urine leak, but our experience suggests that this step is not necessary, and may actually increase the risk of compromising underlying structures. We report our experience with MIPN without collecting system closure for patients at high risk of urine leak, as determined by parameters described in the urologic literature.
METHODS: We reviewed the data for patients over a 10 year period that underwent MIPN, including clinical and radiographic features. We also performed a literature review to identify predictors of postoperative urine leak-defined as persistent drain output or elevated fluid creatinine requiring any intervention. Our surgical technique has been described previously and involves a fibrin glue bolster secured with parenchymal sutures. RESULTS: We identified 210 patients who underwent MIPN between May 2006 and October 2016 and met all inclusion criteria. Urine leak occurred in 3/210 (1.4%) patients overall. No patients deemed high risk by RENAL nephrometry score developed urine leak after surgery (0/13). Patients deemed high risk by Renal Pelvis Score had a urine leak rate of 2.0% (3/150), compared to published rate of 23.6%. Additionally, patients at low risk by RENAL score (<7) had leak rate of 1.3% (1/76), while moderate risk patients (7-8) had leak rate of 1.9% (2/103), compared to the published rates of 7.4 and 13.6%, respectively. Only one patient with a tumor size greater than 7cm (n¼9) and one with tumor size less than 4cm (n¼121) experienced a postoperative urine leak.
CONCLUSIONS: Our technique for MIPN shows superior outcomes with respect to urine leak in high-risk patients compared to traditional techniques that include formal collecting system closure. We have successfully applied our approach to pure lap, hand-assisted, and robotassisted laparoscopic procedures. These results challenge accepted dogma that formal collecting system closure is necessary for the prevention of urine leak formation. Omitting this step decreases the complexity of the closure, shortens warm ischemia time, and may actually reduce the risk of urine leak. One area of simulation that has proven to be difficult is the creation of a high fidelity process that accurately and reproducibly simulates individual anatomy and pathology (i.e. patient specific simulators). Advances in 3-D printing and polymer technology, coupled with software that incorporates imaging data into a computer design, make it possible to develop individualized models from patient imaging data. We present the feasibility of patient-specific preoperative rehearsal using 3D processing & printing in complex partial nephrectomy cases.
METHODS: Three patients with enhancing renal lesions suspicious for renal malignancy with complex tumor morphology or significant comorbidities were chosen for preoperative simulation and rehearsal. DICOM files of patients C.T. angiography (CTA) were imported into 3D processing software to create virtual models of kidney parenchyma incorporating the tumor, renal vasculature, and pelvicalyceal system. Surgical phantoms were created using 3D printing and polymer hydrogels, for patient-specific surgical rehearsal. For whole task preoperative surgical rehearsal, other relevant anatomical elements (bowel, perinephric fat, solid organs and bony structures) were incorporated into a replicated hemiabdomen.
RESULTS: All 3 preoperative simulations were completed prior to the live case. Partial nephrectomy was successful in all 3 cases with an average blood loss of 300cc and WIT of 20 minutes. For the first case, preoperative 3D processing and hydrogel kidney aided in assessing the depth of resection of a completely endophytic tumor and predicted violation of the pelvicalyceal system in the live case. In the 2nd case, the preoperative rehearsals ascertained the feasibility of completing partial nephrectomy in a 9 cm upper pole mass. In the final case, the preoperative rehearsals confirmed the feeding vessel and viability of selective ischemia with his existing coagulopathy and nephropathy.
CONCLUSIONS: This initial trial demonstrates that patientspecific procedural rehearsal is effective for enhancing the performance of surgeons during a complex minimal invasive procedure. This transition from generalized to patient-specific simulation may have the potential to impact patient outcomes by permitting preoperative rehearsal.
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INTRODUCTION AND OBJECTIVES: : A growing collective proficiency in multiparametric magnetic resonance imaging (mpMRI) and targeted biopsies for prostate cancer (PCa) screening has given way to an increasing interest in the application of these technologies for targeted therapy. Various targeted therapies have been developed and evaluated; however, these treatments focus energy at a region of the prostate, as opposed to directly at the tumor. Gold nanoparticle (GNP) therapy is a novel treatment that results in tumor-specific ablation, sparing surrounding tissue and structures. Herein, we report the first two cases in the world using gold nanoparticle-directed focal laser ablation of prostate tumors targeted with ultrasound (US) and MR/US fusion technology.
METHODS: Patients were enrolled in a phase II trial, 0 A Study of MRI/US Fusion Imaging and Biopsy in Combination with Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue.
0 Treatment and follow up plan are as follows: intravenous infusion on day 0, which allows GNP deposition into the tumors with the goal of achieving a 15.2 mg/cc tumor concentration required for excitation/ablation. On day 1, the patient presents for focal laser excitation of the GNPs. Laser catheters Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e375
